Supplementary protection
LT - Anti-BCMA antikūnai, bispecifinės antigeną surišančios molekulės, kurios suriša BCMA ir CD3, ir jų panaudojimas
EN - ANTI-BCMA ANTIBODIES, BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND BCMA AND CD3, AND USES THEREOF
SPC
| (11) |
Number of the document |
C 3337824 |
| (68) |
Number of the document |
3337824
|
| (21) |
Application number for Supplementary Protection Certificate |
PA 2023 509 |
| (22) |
Date of filing the application |
2023-02-23 |
| (41) |
Date of publication of the application |
2023-03-10 |
|
Date of publication of SPC |
2024-10-25 |
| (24) |
Date of coming into effect of SPC |
2036-08-17 |
Applicant
| (71) |
Janssen Pharmaceutica NV,
Turnhoutseweg 30, 2340 Beerse,
BE
|
Grantee
| (73) |
Janssen Biotech, Inc.,
800/850 Ridgeview Drive, Horsham, PA 19044,
US
|
Attorney or representative
| (74) |
Stanislava TELEIŠIENĖ,
UAB "Brainera", Taikos 235-17, LT-05213 Vilnius,
LT
|
Number, date and code of the country of origin of the first authorization to place the medicinal or plant protection product on the market within regional economic community
| (93) |
EU/1/22/1675, 2022-08-23
|
Calculated date of expiry of the SPC
| (94) |
2037-08-24 |
Name of the product protected by the basic patent
| (95) |
Teklistamabas |
